Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2008

View Archived Issues

Further data on pregabalin efficacy in generalized anxiety disorder reported

Adenosine A3 receptor expression correlated with responses to CF-101 in RA patients

QUATRx reports results from two phase I clinical studies of sobetirome

Novel compounds for cancer treatment disclosed in recent patent literature

Genetic variation in drug transporter ABCB1 is linked to antidepressant efficacy

Sinclair's new herpes simplex treatment registered in the E.U.

Viventia Biotech to consider strategic alternatives

Transtec provides a safe alternative in opioid treatment

Recent Novartis patents describe novel agents for asthma therapy

M's Science initiates European phase II stroke recovery study

Novel treatment options for septic shock imparted in recent Abbott and Takeda patents

FDA accepts BLA filing for Dysport in cervical dystonia

AMAG provides additional information on clinical development program for ferumoxytol

CYT-387 shows encouraging ex vivo results in patients with myeloproliferative disorders

Oncolytics meets criteria to proceed to full enrollment in phase II clinical trial of Reolysin

Millennium and Harvard Medical School sign agreement for protein homeostasis research

Abbott is to invest up to USD 40 million in Ibis Biosciences

Kiadis reports successful completion of phase II clinical trial of Rhitol for GvHD

FDA grants priority review for Schering-Plough's Peg-IFN for stage III melanoma

Preclinical antitumor profile of proteasome inhibitor CEP-18770 reported

AVEO initiates phase Ib clinical trial of AV-951 in metastatic renal cell carcinoma

Pfizer obtains Japanese approval for Revatio in pulmonary hypertension

TargeGen commences clinical trial of TG-101348 in myeloproliferative disease

MediciNova's MN-166 reduces persistent black hole formation in MS

Studies show safety and efficacy of elvucitabine in HIV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.